JP2005511629A - 持続作用生成物送達用組成物 - Google Patents

持続作用生成物送達用組成物 Download PDF

Info

Publication number
JP2005511629A
JP2005511629A JP2003545267A JP2003545267A JP2005511629A JP 2005511629 A JP2005511629 A JP 2005511629A JP 2003545267 A JP2003545267 A JP 2003545267A JP 2003545267 A JP2003545267 A JP 2003545267A JP 2005511629 A JP2005511629 A JP 2005511629A
Authority
JP
Japan
Prior art keywords
nanoparticles
particles
pharmaceutical composition
bioactive agent
spray
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003545267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511629A5 (enExample
Inventor
エドワーズ，デービッド，エイ．
バティッキー，リチャード，ピー．
シュミットケ，ジェニファー，エル．
ツァピス，ニコラス，ワイ．，ケイ．
ウィーツ，デービッド，エイ．
フルカック，ジェフリー，エス．
Original Assignee
アドバンスト インハレーション リサーチ，インコーポレイテッド
プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アドバンスト インハレーション リサーチ，インコーポレイテッド, プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ filed Critical アドバンスト インハレーション リサーチ，インコーポレイテッド
Publication of JP2005511629A publication Critical patent/JP2005511629A/ja
Publication of JP2005511629A5 publication Critical patent/JP2005511629A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003545267A 2001-11-20 2002-11-20 持続作用生成物送達用組成物 Pending JP2005511629A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33170701P 2001-11-20 2001-11-20
US36566002P 2002-03-18 2002-03-18
PCT/US2002/037334 WO2003043586A2 (en) 2001-11-20 2002-11-20 Compositions for sustained action product delivery

Publications (2)

Publication Number Publication Date
JP2005511629A true JP2005511629A (ja) 2005-04-28
JP2005511629A5 JP2005511629A5 (enExample) 2005-12-22

Family

ID=26987876

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003545267A Pending JP2005511629A (ja) 2001-11-20 2002-11-20 持続作用生成物送達用組成物

Country Status (6)

Country Link
US (1) US20030166509A1 (enExample)
EP (1) EP1458361A4 (enExample)
JP (1) JP2005511629A (enExample)
AU (1) AU2002364701B8 (enExample)
CA (1) CA2465779A1 (enExample)
WO (1) WO2003043586A2 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007063230A (ja) * 2005-09-02 2007-03-15 Tokyo Univ Of Pharmacy & Life Science 難吸収性薬物含有複合粒子
WO2007111163A1 (ja) 2006-03-17 2007-10-04 Tokyo University Of Science Educational Foundation Administrative Organization ナノコンポジット粒子
JP2009532466A (ja) * 2006-04-04 2009-09-10 エスティーシー．ユーエヌエム 薬物送達用の膨潤性粒子
JP2009541271A (ja) * 2006-06-23 2009-11-26 テイボテク・フアーマシユーチカルズ・リミテツド Ｔｍｃ２７８の水性懸濁液
JP2011509287A (ja) * 2008-01-08 2011-03-24 オシャディ ドラッグ アドミニストレーション リミティッド タンパク質およびペプチドの治療薬の経口投与に関する方法および組成物
US8236504B2 (en) 2003-05-08 2012-08-07 Bio-Rad Laboratories, Inc. Systems and methods for fluorescence detection with a movable detection module
JP2013545751A (ja) * 2010-11-12 2013-12-26 ゲッツ コンサルティング アンド プロジェクト マネジメント 修飾された免疫調節粒子
JP2018507916A (ja) * 2015-03-11 2018-03-22 ベフファル アタ エクソソーム送達技術
WO2021235425A1 (ja) * 2020-05-20 2021-11-25 株式会社リコー 脂質ナノ粒子を含有する粒子及びその製造方法

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
AU2002309172A1 (en) * 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
PT1455755E (pt) 2001-11-20 2013-06-18 Civitas Therapeutics Inc Composições particuladas melhoradas para distribuição pulmonar
US20030236205A1 (en) * 2002-06-21 2003-12-25 Zhang David Y. Hybridization signal amplification method (HSAM) nanostructures for diagnostic and therapeutic uses
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
CA2548281C (en) * 2003-12-09 2013-11-12 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
EP1722762A2 (en) * 2004-03-02 2006-11-22 Massachusetts Institute of Technology Nanocell drug delivery system
US20070053845A1 (en) * 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
CN101031285A (zh) * 2004-10-01 2007-09-05 卫材R&D管理有限公司 含有微粒的组合物及其制备方法
BRPI0517374A (pt) * 2004-10-29 2008-10-07 Harvard College formulação para tratamento ou prevenção de infecção respiratória, método para tratamento
EA200701065A1 (ru) * 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
US8992986B2 (en) * 2004-12-20 2015-03-31 Australian Nuclear Science & Technology Organisation Controlled release of biological entities
US20070120281A1 (en) * 2005-11-08 2007-05-31 Boris Khusid Manufacture of fine particles and nano particles and coating thereof
USRE50189E1 (en) 2006-01-20 2024-10-29 Janssen Sciences Ireland Unlimited Company Long term treatment of HIV-infection with TMC278
JP2009524646A (ja) * 2006-01-27 2009-07-02 ザ・プロヴォスト，フェローズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホーリー・アンド・アンディヴァイデッド・トリニティー・オブ・クイーン・エリザベス，ニア・ダブリン 多孔性微粒子の製造方法
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
EP2162120B1 (en) 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
EP2050437A1 (en) * 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
EP2231169B1 (en) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
US8697098B2 (en) 2011-02-25 2014-04-15 South Dakota State University Polymer conjugated protein micelles
EP2411137B1 (en) 2009-03-27 2016-09-07 Bend Research, Inc. Spray-drying process
US9433588B2 (en) * 2009-11-09 2016-09-06 Virginia Commonwealth Univeristy Delivery of submicrometer and nanometer aerosols to the lungs using hygroscopic excipients or dual stream nasal delivery
US9084944B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
PT2611529T (pt) 2010-09-03 2019-05-09 Bend Res Inc Método de secagem por pulverização
WO2012040502A1 (en) 2010-09-24 2012-03-29 Bend Research, Inc. High-temperature spray drying process and apparatus
CA2828253C (en) 2011-02-25 2016-10-18 South Dakota State University Polymer conjugated protein micelles
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2869849A1 (en) 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide, vilanterol trifenatate and fluticasone furoate
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
KR20220166879A (ko) 2012-06-21 2022-12-19 노쓰웨스턴유니버시티 펩티드 접합된 입자
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
KR20250076678A (ko) 2013-03-13 2025-05-29 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. 염증 치료용 면역-변형된 입자
HRP20192270T4 (hr) 2013-08-13 2024-03-01 Northwestern University Konjugirane čestice peptida
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
DK3212212T3 (da) 2014-10-31 2020-12-21 Univ Monash Pulverformulering
US11364203B2 (en) 2014-10-31 2022-06-21 Bend Reserch, Inc. Process for forming active domains dispersed in a matrix
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
US10751319B2 (en) 2015-06-04 2020-08-25 Crititech, Inc. Collection device and methods for use
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
EP3439635B1 (en) 2016-04-04 2020-12-09 Crititech, Inc. Formulations for solid tumor treatment
SG10201913649TA (en) 2017-06-09 2020-03-30 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
KR102303762B1 (ko) 2017-06-14 2021-09-23 크리티테크, 인크. 폐 장애의 치료 방법
BR112020005814A2 (pt) 2017-10-03 2020-09-24 Crititech, Inc. administração local de partículas antineoplásicas em combinação com administração sistêmica de agentes imunoterapêuticos para o tratamento de câncer
GB201807286D0 (en) 2018-05-03 2018-06-20 Dalsgaard Carl Johan New use
GB201818164D0 (en) 2018-11-07 2018-12-19 Vicore Pharma Ab New composition
GB201916121D0 (en) 2019-11-06 2019-12-18 Vicore Pharma Ab New compositions
GB201916122D0 (en) 2019-11-06 2019-12-18 Nanologica Ab New compositions
GB201916117D0 (en) 2019-11-06 2019-12-18 Vicore Pharma Ab New compositions
GB201916130D0 (en) 2019-11-06 2019-12-18 Vicore Pharma Ab New compositions
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09506098A (ja) * 1993-11-30 1997-06-17 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 局所的および皮下的適用のための気体マイクロスフェア
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO2000010541A1 (en) * 1998-08-25 2000-03-02 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
JP2000143533A (ja) * 1998-11-09 2000-05-23 Asahi Chem Ind Co Ltd ナノスフェア
WO2000033820A2 (de) * 1998-12-08 2000-06-15 Basf Aktiengesellschaft Nanopartikuläre kern-schale systeme sowie deren verwendung in pharmazeutischen und kosmetischen zubereitungen
JP2000511189A (ja) * 1996-05-24 2000-08-29 マサチューセッツ インスティテュート オブ テクノロジー 肺への薬物送達のための空気力学的に軽い粒子
WO2001013891A2 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
WO2001013892A2 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Large porous particles by spray-drying
JP2001513071A (ja) * 1995-07-21 2001-08-28 ブラウン・ユニバーシティ・リサーチ・ファンデーション 転相現象による微粒子の製法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021248A (en) * 1988-09-19 1991-06-04 Enzytech, Inc. Hydrophobic protein microparticles and preparation thereof
AU7908791A (en) * 1990-05-08 1991-11-27 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
EP0740548B1 (en) * 1994-02-28 2002-12-04 Nanopharm AG Drug targeting system, method for preparing same and its use
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
CA2213638C (en) * 1995-02-24 2004-05-04 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
PT752245E (pt) * 1995-07-05 2002-09-30 Europ Economic Community Nanoparticulas biocompativeis e biodegradaveis destinadas a absorcao e administracao de farmacos proteinaceos
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
WO1998011877A1 (en) * 1996-09-18 1998-03-26 Dragoco, Inc. Liposome encapsulated active agent dry powder composition
US6045823A (en) * 1996-09-19 2000-04-04 Dragoco Gerberding & Co. Ag Process for producing solid anhydrous composition, and pharmaceutical and cosmetic products comprising same
AU2464299A (en) * 1998-01-22 1999-08-09 Luminex Corporation Microparticles with multiple fluorescent signals
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6070575A (en) * 1998-11-16 2000-06-06 Aradigm Corporation Aerosol-forming porous membrane with certain pore structure
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
DE10145910A1 (de) * 2000-09-18 2002-06-20 Registrar University Of Delhi Ophtalmologische Formulierung mit verlangsamter Freisetzung und langer Verweildauer sowie Herstellungsverfahren hierfür
US6589562B1 (en) * 2000-10-25 2003-07-08 Salvona L.L.C. Multicomponent biodegradable bioadhesive controlled release system for oral care products

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09506098A (ja) * 1993-11-30 1997-06-17 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 局所的および皮下的適用のための気体マイクロスフェア
JP2001513071A (ja) * 1995-07-21 2001-08-28 ブラウン・ユニバーシティ・リサーチ・ファンデーション 転相現象による微粒子の製法
JP2000511189A (ja) * 1996-05-24 2000-08-29 マサチューセッツ インスティテュート オブ テクノロジー 肺への薬物送達のための空気力学的に軽い粒子
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO2000010541A1 (en) * 1998-08-25 2000-03-02 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
JP2000143533A (ja) * 1998-11-09 2000-05-23 Asahi Chem Ind Co Ltd ナノスフェア
WO2000033820A2 (de) * 1998-12-08 2000-06-15 Basf Aktiengesellschaft Nanopartikuläre kern-schale systeme sowie deren verwendung in pharmazeutischen und kosmetischen zubereitungen
WO2001013891A2 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
WO2001013892A2 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Large porous particles by spray-drying

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Y KAWASHIMA ET AL.: "A New Powder Design Method to Improve Inhalation Efficiency of Pranlukast Hydrate Dry Powder Aerosol", PHARMACEUTICAL RESEARCH, vol. 15, no. 11, JPN6008014020, 1998, pages 1748 - 1752, XP009009759, ISSN: 0001008819, DOI: 10.1023/A:1011916930655 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236504B2 (en) 2003-05-08 2012-08-07 Bio-Rad Laboratories, Inc. Systems and methods for fluorescence detection with a movable detection module
JP2007063230A (ja) * 2005-09-02 2007-03-15 Tokyo Univ Of Pharmacy & Life Science 難吸収性薬物含有複合粒子
WO2007111163A1 (ja) 2006-03-17 2007-10-04 Tokyo University Of Science Educational Foundation Administrative Organization ナノコンポジット粒子
US8343551B2 (en) 2006-03-17 2013-01-01 Tokyo University Of Science Educational Foundation Administrative Organization Nanocomposite particles
JP2009532466A (ja) * 2006-04-04 2009-09-10 エスティーシー．ユーエヌエム 薬物送達用の膨潤性粒子
JP2009541271A (ja) * 2006-06-23 2009-11-26 テイボテク・フアーマシユーチカルズ・リミテツド Ｔｍｃ２７８の水性懸濁液
JP2011509287A (ja) * 2008-01-08 2011-03-24 オシャディ ドラッグ アドミニストレーション リミティッド タンパク質およびペプチドの治療薬の経口投与に関する方法および組成物
JP2013545751A (ja) * 2010-11-12 2013-12-26 ゲッツ コンサルティング アンド プロジェクト マネジメント 修飾された免疫調節粒子
JP2018507916A (ja) * 2015-03-11 2018-03-22 ベフファル アタ エクソソーム送達技術
JP2022093633A (ja) * 2015-03-11 2022-06-23 ベフファル アタ エクソソーム送達技術
JP7485719B2 (ja) 2015-03-11 2024-05-16 ベフファル アタ エクソソーム送達技術
JP2024102230A (ja) * 2015-03-11 2024-07-30 ベフファル アタ エクソソーム送達技術
WO2021235425A1 (ja) * 2020-05-20 2021-11-25 株式会社リコー 脂質ナノ粒子を含有する粒子及びその製造方法
JPWO2021235425A1 (enExample) * 2020-05-20 2021-11-25
CN115666535A (zh) * 2020-05-20 2023-01-31 株式会社理光 含有脂质纳米颗粒的颗粒及其生产方法
CN115666535B (zh) * 2020-05-20 2024-06-18 株式会社理光 含有脂质纳米颗粒的颗粒及其生产方法

Also Published As

Publication number Publication date
AU2002364701B8 (en) 2006-06-22
AU2002364701B2 (en) 2005-10-13
WO2003043586A2 (en) 2003-05-30
WO2003043586A9 (en) 2004-02-26
EP1458361A4 (en) 2007-04-25
US20030166509A1 (en) 2003-09-04
WO2003043586A3 (en) 2003-08-14
CA2465779A1 (en) 2003-05-30
EP1458361A2 (en) 2004-09-22
AU2002364701A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
AU2002364701B2 (en) Compositions for sustained action product delivery
KR100697479B1 (ko) 많은 치료학적 양의 에어로졸을 효과적으로 전달하는 방법
CA2277801C (en) Preparation of particles for inhalation
US7052678B2 (en) Particles for inhalation having sustained release properties
US5985309A (en) Preparation of particles for inhalation
EP1089712B1 (en) Large porous particles emitted from an inhaler
JP4416325B2 (ja) 安定な噴霧乾燥タンパク質製剤
US6652837B1 (en) Preparation of novel particles for inhalation
US20040018243A1 (en) Modulation of release from dry powder formulations
JP2006513236A (ja) 不溶性活性物質を伴う医薬製剤
AU768299B2 (en) Formulation for spray-drying large porous particles
JP2006249099A (ja) 持続放出特性を有する吸入用粒子
WO2002067902A2 (en) Modulation of release from dry powder formulations
JP2006503865A (ja) 吸入のための徐放性の多孔性微粒子
AU2002242253A1 (en) Modulation of release from dry powder formulations
JP2003507412A (ja) 多孔性粒子を形成するための単純アミノ酸の使用
WO2002078675A2 (en) Particles for inhalation having sustained release properties
JP2005520847A (ja) 肺投与用ｈＧＨ（ヒト成長ホルモン）製剤
CA2403349C (en) Preparation of particles for inhalation
EP1273290A1 (en) Large porous particles emitted from an inhaler
EP1498115A1 (en) Preparation of particles for inhalation

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080625

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080725

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080820

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080924

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20081008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090302